UnknownPhase 3NCT00332306

Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment

Studying Primary genito-urinary tuberculosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tuberculosis Research Centre, India
Principal Investigator
Soumya Swaminathan, MD, M.D
Tuberculosis Research Centre, India
Intervention
Didanosine, Lamivudine, Efavirenz(drug)
Enrollment
180 target
Eligibility
18-61 years · All sexes
Timeline
2006 – 2011

Study locations (1)

Collaborators

National AIDS Control Organisation · Indian Council of Medical Research

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00332306 on ClinicalTrials.gov

Other trials for Primary genito-urinary tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Primary genito-urinary tuberculosis →

← Back to all trials